vs
Side-by-side financial comparison of Envela Corp (ELA) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $80.5M, roughly 1.2× Envela Corp). Vericel Corp runs the higher net margin — 25.0% vs 7.4%, a 17.6% gap on every dollar of revenue. On growth, Envela Corp posted the faster year-over-year revenue change (66.6% vs 23.3%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-3.7M). Over the past eight quarters, Envela Corp's revenue compounded faster (42.1% CAGR vs 34.6%).
Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
ELA vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.5M | $92.9M |
| Net Profit | $6.0M | $23.2M |
| Gross Margin | 20.5% | 78.7% |
| Operating Margin | 9.4% | 24.1% |
| Net Margin | 7.4% | 25.0% |
| Revenue YoY | 66.6% | 23.3% |
| Net Profit YoY | 274.6% | 17.3% |
| EPS (diluted) | $0.22 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $80.5M | $92.9M | ||
| Q3 25 | $57.4M | $67.5M | ||
| Q2 25 | $54.9M | $63.2M | ||
| Q1 25 | $48.3M | $52.6M | ||
| Q4 24 | $48.3M | $75.4M | ||
| Q3 24 | $46.9M | $57.9M | ||
| Q2 24 | $45.3M | $52.7M | ||
| Q1 24 | $39.9M | $51.3M |
| Q4 25 | $6.0M | $23.2M | ||
| Q3 25 | $3.4M | $5.1M | ||
| Q2 25 | $2.8M | $-553.0K | ||
| Q1 25 | $2.5M | $-11.2M | ||
| Q4 24 | $1.6M | $19.8M | ||
| Q3 24 | $1.7M | $-901.0K | ||
| Q2 24 | $1.6M | $-4.7M | ||
| Q1 24 | $1.9M | $-3.9M |
| Q4 25 | 20.5% | 78.7% | ||
| Q3 25 | 22.8% | 73.5% | ||
| Q2 25 | 22.6% | 73.7% | ||
| Q1 25 | 24.8% | 69.0% | ||
| Q4 24 | 23.1% | 77.6% | ||
| Q3 24 | 24.4% | 71.9% | ||
| Q2 24 | 25.1% | 69.5% | ||
| Q1 24 | 25.9% | 68.9% |
| Q4 25 | 9.4% | 24.1% | ||
| Q3 25 | 7.3% | 5.1% | ||
| Q2 25 | 5.9% | -3.2% | ||
| Q1 25 | 6.5% | -24.3% | ||
| Q4 24 | 3.9% | 24.5% | ||
| Q3 24 | 4.3% | -4.3% | ||
| Q2 24 | 4.2% | -11.5% | ||
| Q1 24 | 5.9% | -10.7% |
| Q4 25 | 7.4% | 25.0% | ||
| Q3 25 | 5.8% | 7.5% | ||
| Q2 25 | 5.0% | -0.9% | ||
| Q1 25 | 5.2% | -21.4% | ||
| Q4 24 | 3.3% | 26.3% | ||
| Q3 24 | 3.6% | -1.6% | ||
| Q2 24 | 3.5% | -8.9% | ||
| Q1 24 | 4.8% | -7.5% |
| Q4 25 | $0.22 | $0.46 | ||
| Q3 25 | $0.13 | $0.10 | ||
| Q2 25 | $0.11 | $-0.01 | ||
| Q1 25 | $0.10 | $-0.23 | ||
| Q4 24 | $0.07 | $0.40 | ||
| Q3 24 | $0.06 | $-0.02 | ||
| Q2 24 | $0.06 | $-0.10 | ||
| Q1 24 | $0.07 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $9.9M | — |
| Stockholders' EquityBook value | $67.1M | $354.6M |
| Total Assets | $96.0M | $488.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | $19.8M | $110.6M |
| Q4 25 | $9.9M | — | ||
| Q3 25 | $12.5M | — | ||
| Q2 25 | $13.0M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $14.3M | — | ||
| Q1 24 | $14.6M | — |
| Q4 25 | $67.1M | $354.6M | ||
| Q3 25 | $61.1M | $321.9M | ||
| Q2 25 | $57.8M | $306.8M | ||
| Q1 25 | $55.1M | $295.5M | ||
| Q4 24 | $52.7M | $292.0M | ||
| Q3 24 | $51.1M | $257.5M | ||
| Q2 24 | $50.2M | $243.0M | ||
| Q1 24 | $49.3M | $233.9M |
| Q4 25 | $96.0M | $488.0M | ||
| Q3 25 | $90.9M | $453.3M | ||
| Q2 25 | $82.7M | $435.6M | ||
| Q1 25 | $79.7M | $424.6M | ||
| Q4 24 | $77.9M | $432.7M | ||
| Q3 24 | $77.4M | $390.4M | ||
| Q2 24 | $73.8M | $376.8M | ||
| Q1 24 | $74.7M | $356.7M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.27× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $15.0M |
| Free Cash FlowOCF − Capex | $-3.7M | $12.8M |
| FCF MarginFCF / Revenue | -4.6% | 13.8% |
| Capex IntensityCapex / Revenue | 0.2% | 2.4% |
| Cash ConversionOCF / Net Profit | -0.59× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $1.4M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | $15.0M | ||
| Q3 25 | $2.4M | $22.1M | ||
| Q2 25 | $2.6M | $8.2M | ||
| Q1 25 | $1.1M | $6.6M | ||
| Q4 24 | $3.7M | $22.2M | ||
| Q3 24 | $3.4M | $10.2M | ||
| Q2 24 | $-789.5K | $18.5M | ||
| Q1 24 | $3.8M | $7.2M |
| Q4 25 | $-3.7M | $12.8M | ||
| Q3 25 | $2.2M | $19.5M | ||
| Q2 25 | $2.1M | $81.0K | ||
| Q1 25 | $746.6K | $-7.6M | ||
| Q4 24 | $3.2M | $8.5M | ||
| Q3 24 | $1.5M | $-9.2M | ||
| Q2 24 | $-1.3M | $1.8M | ||
| Q1 24 | $3.3M | $-6.8M |
| Q4 25 | -4.6% | 13.8% | ||
| Q3 25 | 3.8% | 28.8% | ||
| Q2 25 | 3.9% | 0.1% | ||
| Q1 25 | 1.5% | -14.5% | ||
| Q4 24 | 6.7% | 11.2% | ||
| Q3 24 | 3.1% | -15.9% | ||
| Q2 24 | -2.9% | 3.4% | ||
| Q1 24 | 8.4% | -13.3% |
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.4% | 3.9% | ||
| Q2 25 | 0.8% | 12.9% | ||
| Q1 25 | 0.8% | 27.0% | ||
| Q4 24 | 1.0% | 18.3% | ||
| Q3 24 | 4.2% | 33.5% | ||
| Q2 24 | 1.1% | 31.8% | ||
| Q1 24 | 1.1% | 27.3% |
| Q4 25 | -0.59× | 0.65× | ||
| Q3 25 | 0.72× | 4.35× | ||
| Q2 25 | 0.94× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 2.34× | 1.12× | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | -0.50× | — | ||
| Q1 24 | 1.99× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
